ACE–inhibitor treatment attenuates atrial structural remodeling in patients with lone chronic atrial fibrillation
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Chronic atrial fibrillation (AF) is characterized by a remodeling process which involves the development of fibrosis. Since angiotensin II has been suspected to be involved in this process, the aim of our study was to investigate a possible influence of an ACE–I therapy in patients with chronic AF regarding the occurrence of left atrial structural remodeling.
Atrial tissue samples were obtained from patients with lone chronic AF or sinus rhythm (SR). Collagen I, vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) protein expression were measured by quantitative Western Blotting techniques and calculated as mean ± SEM. Histological tissue samples were used for calculating microvessel density (microvessel/mm2 ± SEM).
In AF, the collagen amount was higher (1.78 ± 0.21; p = 0.01) vs. SR (0.37 ± 0.07) accompanied by declining microcapillary density (AF: 145 ± 13 vs. SR: 202 ± 9; p = 0.01). Additionally, a negative correlation (p = 0.01) between collagen content and microcapillary density was observed. To investigate the influence of an ACE–I therapy on this remodeling process, patient groups were divided into AF and SR both with or without ACE–I. Interestingly, there was a significantly lower expression of collagen I in AF with ACE–I (1.04 ± 0.26) vs. AF without ACE–I treatment (2.07 ± 0.24, p = 0.02). The microcapillaries were not diminished in AF with ACE–I (180 ± 15) vs. SR with ACE–I (196 ± 9), but there was a significant rarification in AF without ACE–I (123 ± 18; p = 0.03). The expression of VEGF and bFGF did not reveal any significant differences.
In patients undergoing ACE–I treatment: atrial structural remodeling was attenuated and the loss of atrial microcapillaries was prevented.
- Allessie M, Ausma A, Schotten U (2002) Electrical, contractile and structural remodeling promote stability of atrial fibrillation. Cardiovasc Res 54:230–246 CrossRef
- Belichard P, Savard P, Cardinal R et al. (1994) Markedly different effects on ventricular remodeling result in a decrease in inducibility of ventricular arrhythmias. J Am Coll Cardiol 23:505–513
- Boldt A, Wetzel U, Lauschke J et al. (2004) Fibrosis in left atrial tissue of patients with atrial fibrillation with and without underlying mitral valve disease. Heart 90:400–405 CrossRef
- Boldt A, Wetzel U, Weigl J et al. (2003) Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease. J Am Coll Cardiol 42:1785–1792 CrossRef
- Dai Y, Wang X, Cao L, Yang M, Wu T (2004) Expression of extracellular signalregulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Huazhong Univ Sci Technolog Med Sci 24:32–36
- Goette A, Arndt M, Roecken C et al. (2000) Regulation of angiotensin II receptor subtypes during atrial fibrillation in humans. Circulation 101:2678–2681
- Goette A, Staack T, Rocken C et al. (2000) Increased expression of extracellular signal-regulated kinase and angiotensinconverting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 35:1669–1677 CrossRef
- Grammer JB, Bohm J, Dufour A et al. (2005) Atrial fibrosis in heart surgery patients. Decreased collagen III/I ratio in postoperative atrial fibrillation. Basic Res Cardiol 100:288–294 CrossRef
- Kottkamp H, Hindricks G, Autschbach R, et al. (2002) Specific linear left atrial lesions in atrial fibrillation: intraoperative radiofrequency ablation using minimally invasive surgical techniques. J Am Coll Cardiol 40:475–480 CrossRef
- Li D, Fareh S, Leung TK et al. (1999) Promotion of atrial fibrillation by heart failure in dogs. Atrial remodeling of a different sorts. Circulation 100:87–95
- Li D, Shinagawa K, Pang L et al. (2001) Effects of angiotensin converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacing-induced congestive heart failure. Circulation 104:2608–2614
- Nattel S (2002) New ideas about atrial fibrillation 50 years on. Nature 415:219–226 CrossRef
- Sabbah HN, Sharov VG, Lesch M, Goldstein S (1995) Progression of heart failure: a role for interstitional fibrosis. Mol Cell Biochem 147:29–34 CrossRef
- Sakabe M, Fujiki A, Nishida K et al. (2004) Enalapril prevents perpetuation of atrial fibrillation by suppressing atrial fibrosis and over-expression of connexin 43 in a canine model of atrial pacinginduced left ventricular dysfunction. J Cardiovasc Pharmacol 43:851–859
- Shi Y, Li D, Tardif J-C, Nattel S (2002) Enalapril effects on atrial remodeling and atrial fibrillation in experimental congestive heart failure. Cardiovasc Res 54:456–461 CrossRef
- Youn TJ, Kim HS, Oh BH (1999) Ventricular remodeling and transforming growth factor-beta 1 mRNA expression after nontransmural myocardial infarction in rats: effects of angiotensin converting enzyme inhibition and angiotensin II type 1receptor blockade. Basic Res Cardiol 94:246–253 CrossRef
- Van Noord T, Crijns HGJM, van den Berg MP et al. (2005) Pretreatment with ACE inhibitors improves acute outcome of electrical cardioversion in patients with persistent atrial fibrillation. BMC Cardiovasc Disord 5:3 CrossRef
- Wang JM, Wang Y, Zhu ZS et al. (2004) Diverse effects of long-term treatment with imidapril and irbesartan on cell growth signal, apoptosis and collagen type I expression in the left ventricle of spontaneously hypertensive rats. Life Sci 75:407–420 CrossRef
- ACE–inhibitor treatment attenuates atrial structural remodeling in patients with lone chronic atrial fibrillation
Basic Research in Cardiology
Volume 101, Issue 3 , pp 261-267
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- growth factor
- Industry Sectors